Dear Colleague,

The Biomarker Summit 2017, to be held on March 20-22, 2017 in San Diego, CA at the Hilton San Diego Resort & Spa, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.

Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:

General Session:
Plenary Keynote Session
Big Data Analytics & Bioinformatics for Biomarkers Development
Emerging Technologies in Biomarker Development
Overcoming Challenges of Clinical Validation & Translation
Panel Discussion: Companion Diagnostics Development & Partnering Strategies
Overcoming Commercialization Challenges in Biomarker Development
-Regulatory & Reimbursement Trends in Biomarker Development
-Current Landscape of Biomarkers IP & Future Trends
10th Oncology Biomarkers
Circulating Tumor Cells & Microvesicles
Liquid Biopsy: Circulating DNA & MicroRNA
Immuno-oncology Biomarkers
Novel Technologies in Oncology Biomarkers
6th Neurological Biomarkers
Imaging Approaches in CNS Drug Discovery & Development
CSF & Blood Based Biomarker Approaches
Monitoring Progression in Neurodegenerative Disorders
Novel Technologies in Neurological Biomarkers
6th Inflammatory & Immunological Biomarkers
Biomarkers of Early Progressive Inflammatory & Immunological Diseases
Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
Microbiomes in Immune Modulation & Inflammatory Diseases
Inflammatory Biomarkers in Respiratory Diseases
Cardiovascular Biomarkers
Biomarker R&D in the Cardiovascular Space
Heart Failure & Acute Coronary Syndromes
Metabolic Syndrome & Cardiovascular Risk
Novel Technologies in Cardiovascular Biomarkers


Best regards,

The 2017 Advisory Committee